Is BPC-157 FDA Approved? The Complete Record

BPC-157 is not FDA approved. It has never been approved as a drug, a dietary supplement or a food additive. The FDA placed BPC-157 in Category 2 of its bulk drug substance evaluation in September 2023, flagging significant safety concerns. The nominations were later withdrawn, but the FDA proceeded with its evaluation. The Pharmacy Compounding Advisory Committee voted 8-6 in July 2026 to recommend inclusion on the 503A bulks list, though that vote is advisory and non-binding.

FDA Bulk Drug Substance Evaluation

What the Bulk Drug Substance List Is

The FDA evaluates substances nominated for use in compounding under section 503A and 503B of the FD&C Act. These sections allow licensed pharmacies and outsourcing facilities to compound drugs using bulk substances that appear on a positive list. Substances not on the list cannot legally be compounded.

BPC-157 Category 2 Classification

In September 2023, the FDA placed BPC-157 in Category 2 of its bulk drug substance safety review. Category 2 means the substance raises significant safety concerns based on available data. The FDA stated that BPC-157 "may pose risk for immunogenicity" and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans." While in Category 2, the substance could not be legally compounded under 503A or 503B.

By April 2026, the nominations for BPC-157 were withdrawn by their sponsors, moving BPC-157 to a "nominated but withdrawn" status. Removal from Category 2 does not automatically confer Category 1 (approved for compounding) status. Each substance requires individual PCAC review before reclassification.

Pharmacy Compounding Advisory Committee

The FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026 to evaluate BPC-157 (free base) and BPC-157 acetate for potential inclusion on the 503A bulks list, specifically for ulcerative colitis. Despite the nominations being withdrawn, the FDA proceeded with its evaluation. The FDA staff recommended against inclusion, but the committee voted 8-6 (with 1 abstention) to recommend that BPC-157 be added to the 503A bulks list.

This vote is indicative of the committee's opinion but is not binding in nature. Ultimately, it is the FDA that takes the final call on the addition of any substances to the bulks list. As of October 2026, BPC-157 is still excluded from the 503A bulks list. There is no indication of when the FDA will announce its final decision.

FDA Warning Letters to Peptide Sellers

What a Warning Letter Means

An FDA warning letter is not a fine or a ban. It is a formal notice that the agency has found violations of federal law and expects corrective action. Companies that ignore warning letters face potential injunctions, seizures or criminal prosecution. The FDA publishes all warning letters on its enforcement page.

Companies That Received Letters

From 2019 to 2026, the FDA issued warning notices and untitled notices to organizations that market or create BPC-157. The breaches fall into two categories: research chemical suppliers that make health claims and compounding pharmacies that use BPC-157 as a raw ingredient without permission.

What the Letters Actually Say

The warning letters follow a similar format. The FDA describes the product, which is usually BPC-157 sold as powder or injectable solution, then points out the health claims made by the company's website or other marketing material, before concluding that it fits into the definition of a drug according to the 21 U.S.C. § 321(g)(1). The letters then instruct the companies to immediately cease distribution of the product and send a plan of corrective action within 15 days.

Claims that prompt regulatory action include claims related to healing, recovery, inflammation, and tissue repair. According to the FD&C Act, any product marketed with claims used to diagnose, cure, mitigate, treat, or prevent disease is classified as a drug regardless of the term used in its description. A label “for research purposes only” does not negate the effect of health claims made elsewhere on the same site.

FDA Import Alerts

Detention Without Physical Examination

The FDA can place unapproved drugs on import alert, which allows US Customs and Border Protection to detain shipments at the border without physically inspecting them. Import alerts are listed on the FDA's import alert database. Peptide shipments from overseas suppliers have been detained under alerts targeting unapproved new drugs. This mechanism affects both commercial importers and individuals ordering small quantities for personal use.

What This Means for Buyers

Legal Risk by Channel

The FDA's position creates a tiered risk structure. Buying from a US-based research peptide vendor is a grey area: the vendor faces enforcement risk, but individual buyers purchasing small quantities for research have not been targeted by warning letters so far. Buying from overseas exposes orders to customs detention. Buying from a compounding pharmacy without a valid prescription violates pharmacy law. Our legal risks page covers each scenario.

The Research Chemical Loophole

The vendors proposing BPC-157 as a "research chemical" or "for research purposes only" are not following the rules. The term "for research purposes" shows that the vendors don't consider their products to be drugs. However, the FDA has stated that the term "for research purposes" does not give any legal protection to the same vendor when it puts health claims on its website or social media mentioning its products. Our research use disclaimer guide gives you the detailed explanation of how this system works.